Physician profile
Todd E Chenicek
NPI 1437100724
$4,231.60
in general payments reported to CMS, 2019-2025
23 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $857 · 2023: $1,318 · 2024: $925 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.23 | 2021-2025 | |
| Celgene Corporation | $395.67 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $391.09 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.47 | 2021-2025 | Xifaxan |
| Daiichi Sankyo INC. | $209.40 | 2021-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $164.64 | 2023-2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $160.60 | 2021-2023 | |
| Pfizer INC. | $135.10 | 2023-2025 | |
| Ardelyx, INC. | $124.64 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $119.98 | 2023-2024 | Stelara |
| Genzyme Corporation | $105.15 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $92.76 | 2021-2024 | Dificid |
| Redhill Biopharma INC. | $89.37 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $83.23 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $67.15 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.09 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $47.57 | 2021-2023 | Suflave |
| Madrigal Pharmaceuticals | $37.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $35.77 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $31.52 | 2024 | |
| Axonics, INC. | $24.50 | 2022 | |
| Pharmacosmos Therapeutics INC. | $23.02 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Chenicek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.